This message was posted by a user wishing to remain anonymous
What are the regulatory implications of closing out a clinical site that has not enrolled any patients and qualifying another site in an IDE trial? Does this require prior approval by FDA or is including this in an annual report sufficient? The total number of sites approved for the IDE will not be impacted. Thanks